CD3 monitoring and thymoglobulin therapy in cardiac transplantation: Clinical outcomes and pharmacoeconomic implications

Transplantation Proceedings

Volumn 36, Issue 10, 2004, Pages 3245-3249

  Uber, Walter E ^a   Uber, L A ^a   VanBakel, A B ^a   Crumbley III, A J ^b   Pereira, N L ^a   Ikonomidis, J S ^b   Feldman, D S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; BLOOD; COST; DRUG MONITORING; ECONOMICS; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; REOPERATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ANTIGENS, CD; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; COSTS AND COST ANALYSIS; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REOPERATION; RETROSPECTIVE STUDIES; SOUTH CAROLINA; TREATMENT OUTCOME;

EID: 21244477194     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.11.099     Document Type: Article

References (20)

1. Taylor DO, Kfoury AG, Pisani B, et al: Antilymphocyte antibody prophylaxis: review of the adult experience in heart transplantation. Transplant Proc 29(suppl 8A):13S, 1997
2. Cosimi AB, Wortis HH, Delmonico FL, et al: Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery 80:155, 1976
3. Kreis H, Mansouri R, Descamps JM, et al: Antithymocyte globulin in cadaver kidney transplantation: a randomized trial based on T-cell monitoring. Kidney Int 19:438, 1981
4. Clark KR, Forsythe JLR, Shenton BK, et al: Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int 6:18, 1993
5. Gaber AO, First MR, Tesi RJ, et al: Results of the double blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66:29, 1998
6. Brennan DC, Flavin K, Lowell JA, et al: A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67:1011, 1999
7. Vernier I, Giraud P, Eche JP, et al: Hematological side effects of antilymphocyte globulins: prevalence and impact on therapeutic control. Transplant Proc 17:2765, 1985
8. Rubin RH, Cosimi AB, Hirsch MS, et al: Effects of antilymphocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 31:143, 1981
9. Pass RF, Whitley RJ, Diethelm AG, et al: Cytomegalovirus infection in patients with renal transplants: potentiation by antithymocyte globulin and an incompatible graft. J Infect Dis 142:9, 1980
10. O'Donoghue DJ, Johnson RWG, Mallick NP, et al: Rabbit antithymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplant Proc 21:1736, 1989
11. Cockfield SM, Preiksaitis JK, Jewell LD, et al: Posttransplant lymphoproliferative disorder in renal allograft recipients: clinical experience and risk factor analysis in a single center. Transplantation 56:88, 1993
12. Abouna GM, Al-Abdullah IH, Kelly-Sullivan D, et al: Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 59:1564, 1995
13. Djamali A, Turc-Baron C, Portales P, et al: Low dose antithymocyte globulins in renal transplantation, daily versus intermittent administration based on T-cell monitoring. Transplantation 69:700, 2000
14. Krasinskas AM, Kreisel D, Acker MA, et al: CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation 73:1339, 2002
15. Billingham ME, Gary NRB, Hammond ME, et al: A working formulation for the standardization of the nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 9:587, 1990
16. Thomas F, Griesedieck C, Thomas J, et al: Use of newer immunologic assays for individualized immunomodulation after renal transplant. Transplant Proc 26:1520, 1984
17. Hammond EH, Yowell RL, Nunoda S, et al: Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 8:430, 1989
18. Michaels PJ, Espejo MJ, Kobashigawa J, et al: Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22:58, 2003
19. Bonnefoy-Berard N, Revillard JP: Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15:435, 1996
20. Ram Peddi V, Bryant M, Roy-Chaudhury P, et al: Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 73: 1514, 2002